220 related articles for article (PubMed ID: 31343993)
21. Neurotrophin receptors and heparanase: a functional axis in human medulloblastoma invasion.
Marchetti D; Mrak RE; Paulsen DD; Sinnappah-Kang ND
J Exp Clin Cancer Res; 2007 Mar; 26(1):5-23. PubMed ID: 17550129
[TBL] [Abstract][Full Text] [Related]
22. Dissecting the genomic complexity underlying medulloblastoma.
Jones DT; Jäger N; Kool M; Zichner T; Hutter B; Sultan M; Cho YJ; Pugh TJ; Hovestadt V; Stütz AM; Rausch T; Warnatz HJ; Ryzhova M; Bender S; Sturm D; Pleier S; Cin H; Pfaff E; Sieber L; Wittmann A; Remke M; Witt H; Hutter S; Tzaridis T; Weischenfeldt J; Raeder B; Avci M; Amstislavskiy V; Zapatka M; Weber UD; Wang Q; Lasitschka B; Bartholomae CC; Schmidt M; von Kalle C; Ast V; Lawerenz C; Eils J; Kabbe R; Benes V; van Sluis P; Koster J; Volckmann R; Shih D; Betts MJ; Russell RB; Coco S; Tonini GP; Schüller U; Hans V; Graf N; Kim YJ; Monoranu C; Roggendorf W; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; von Deimling A; Witt O; Maass E; Rössler J; Ebinger M; Schuhmann MU; Frühwald MC; Hasselblatt M; Jabado N; Rutkowski S; von Bueren AO; Williamson D; Clifford SC; McCabe MG; Collins VP; Wolf S; Wiemann S; Lehrach H; Brors B; Scheurlen W; Felsberg J; Reifenberger G; Northcott PA; Taylor MD; Meyerson M; Pomeroy SL; Yaspo ML; Korbel JO; Korshunov A; Eils R; Pfister SM; Lichter P
Nature; 2012 Aug; 488(7409):100-5. PubMed ID: 22832583
[TBL] [Abstract][Full Text] [Related]
23. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
[TBL] [Abstract][Full Text] [Related]
24. Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma.
Li Y; Jiang T; Shao L; Liu Y; Zheng C; Zhong Y; Zhang J; Chang Q
J Neurooncol; 2016 Sep; 129(3):423-431. PubMed ID: 27406588
[TBL] [Abstract][Full Text] [Related]
25. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.
Pugh TJ; Weeraratne SD; Archer TC; Pomeranz Krummel DA; Auclair D; Bochicchio J; Carneiro MO; Carter SL; Cibulskis K; Erlich RL; Greulich H; Lawrence MS; Lennon NJ; McKenna A; Meldrim J; Ramos AH; Ross MG; Russ C; Shefler E; Sivachenko A; Sogoloff B; Stojanov P; Tamayo P; Mesirov JP; Amani V; Teider N; Sengupta S; Francois JP; Northcott PA; Taylor MD; Yu F; Crabtree GR; Kautzman AG; Gabriel SB; Getz G; Jäger N; Jones DT; Lichter P; Pfister SM; Roberts TM; Meyerson M; Pomeroy SL; Cho YJ
Nature; 2012 Aug; 488(7409):106-10. PubMed ID: 22820256
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
[TBL] [Abstract][Full Text] [Related]
27. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis.
Clifford SC; Lusher ME; Lindsey JC; Langdon JA; Gilbertson RJ; Straughton D; Ellison DW
Cell Cycle; 2006 Nov; 5(22):2666-70. PubMed ID: 17172831
[TBL] [Abstract][Full Text] [Related]
28. β-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma.
Zinke J; Schneider FT; Harter PN; Thom S; Ziegler N; Toftgård R; Plate KH; Liebner S
Mol Cancer; 2015 Feb; 14(1):17. PubMed ID: 25645196
[TBL] [Abstract][Full Text] [Related]
29. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
Kool M; Korshunov A; Remke M; Jones DT; Schlanstein M; Northcott PA; Cho YJ; Koster J; Schouten-van Meeteren A; van Vuurden D; Clifford SC; Pietsch T; von Bueren AO; Rutkowski S; McCabe M; Collins VP; Bäcklund ML; Haberler C; Bourdeaut F; Delattre O; Doz F; Ellison DW; Gilbertson RJ; Pomeroy SL; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):473-84. PubMed ID: 22358457
[TBL] [Abstract][Full Text] [Related]
30. Contrast enhancement pattern predicts poor survival for patients with non-WNT/SHH medulloblastoma tumours.
Łastowska M; Jurkiewicz E; Trubicka J; Daszkiewicz P; Drogosiewicz M; Malczyk K; Grajkowska W; Matyja E; Cukrowska B; Pronicki M; Perek-Polnik M; Perek D; Dembowska-Bagińska B
J Neurooncol; 2015 May; 123(1):65-73. PubMed ID: 25862008
[TBL] [Abstract][Full Text] [Related]
31. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas.
Adamson DC; Shi Q; Wortham M; Northcott PA; Di C; Duncan CG; Li J; McLendon RE; Bigner DD; Taylor MD; Yan H
Cancer Res; 2010 Jan; 70(1):181-91. PubMed ID: 20028867
[TBL] [Abstract][Full Text] [Related]
32. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
33. Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours.
Goschzik T; Zur Mühlen A; Kristiansen G; Haberler C; Stefanits H; Friedrich C; von Hoff K; Rutkowski S; Pfister SM; Pietsch T
Neuropathol Appl Neurobiol; 2015 Feb; 41(2):135-44. PubMed ID: 24894640
[TBL] [Abstract][Full Text] [Related]
34. Histologic Correlates of Molecular Group 4 Pediatric Medulloblastoma: A Retrospective Canadian Review.
Triscott J; Yip S; Johnston D; Michaud J; Rassekh SR; Hukin J; Dunn S; Dunham C
Pediatr Dev Pathol; 2021; 24(4):309-317. PubMed ID: 33749384
[TBL] [Abstract][Full Text] [Related]
35. Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach.
Kaur K; Kakkar A; Kumar A; Mallick S; Julka PK; Gupta D; Suri A; Suri V; Sharma MC; Sarkar C
Brain Pathol; 2016 May; 26(3):334-43. PubMed ID: 26222673
[TBL] [Abstract][Full Text] [Related]
36. Medulloblastoma molecular dissection: the way toward targeted therapy.
Remke M; Ramaswamy V; Taylor MD
Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581
[TBL] [Abstract][Full Text] [Related]
37. Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup.
da Silva LS; Mançano BM; de Paula FE; Dos Reis MB; de Almeida GC; Matsushita M; Junior CA; Evangelista AF; Saggioro F; Serafini LN; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; de Lima MA; Taylor MD; Leal LF; Reis RM
J Mol Diagn; 2020 Jul; 22(7):957-966. PubMed ID: 32380172
[TBL] [Abstract][Full Text] [Related]
38. Advanced MRI Findings in Medulloblastomas: Relationship to Genetic Subtypes, Histopathology, and Immunohistochemistry.
Reis J; Stahl R; Zimmermann H; Ruf V; Thon N; Kunz M; Liebig T; Forbrig R
J Neuroimaging; 2021 Mar; 31(2):306-316. PubMed ID: 33465267
[TBL] [Abstract][Full Text] [Related]
39. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Martin DC; Castelo-Branco P; Zhang CH; Fraser M; Tse K; Poon R; Shih DJ; Baskin B; Ray PN; Bouffet E; Dirks P; von Bueren AO; Pfaff E; Korshunov A; Jones DT; Northcott PA; Kool M; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognár L; Cho BK; Eberhart CG; Conter CF; Fouladi M; French PJ; Grajkowska WA; Gupta N; Hauser P; Jabado N; Vasiljevic A; Jung S; Kim SK; Klekner A; Kumabe T; Lach B; Leonard JR; Liau LM; Massimi L; Pollack IF; Ra YS; Rubin JB; Van Meir EG; Wang KC; Weiss WA; Zitterbart K; Bristow RG; Alman B; Hawkins CE; Malkin D; Clifford SC; Pfister SM; Taylor MD; Tabori U
Acta Neuropathol Commun; 2014 Dec; 2():174. PubMed ID: 25539912
[TBL] [Abstract][Full Text] [Related]
40. Clinicomorphological and molecular analysis of medulloblastoma and association with survival: A single tertiary care center experience.
Badiger S; Gudipati A; Uppin M; Konatam ML; Yeramneni VK; Bhattacharjee S; Saradhi MV; Patnaik S; Irukulla M
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S592-S602. PubMed ID: 38384024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
